Physician profile
Khanh Thoai Truong
NPI 1023637550
$10,342.98
in general payments reported to CMS, 2019-2025
21 companies · $4,938 in 2025
The $4,938 reported for 2025 was more than what 92% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2023: $1,600 · 2024: $3,690 · 2025: $4,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,015 · Travel and Lodging: $2,168 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,014.67 |
| Travel and Lodging | $2,167.97 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,937.55 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $813.10 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $806.61 | 2023-2025 | Xywav |
| Astrazeneca Pharmaceuticals Lp | $806.12 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $589.20 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Itamar Medical INC | $544.18 | 2024-2025 | Watchpatone |
| Lilly USA, LLC | $540.65 | 2024-2025 | Zepbound, Kisunla, Jardiance |
| Amgen INC. | $422.44 | 2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $253.28 | 2023-2025 | |
| Abbvie INC. | $250.57 | 2023-2025 | Qulipta, Ubrelvy |
| Idorsia Pharmaceuticals US INC | $244.41 | 2023-2025 | Quviviq, Quviviq |
| Viiv Healthcare Company | $243.82 | 2024-2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $231.66 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.35 | 2024-2025 | Jardiance |
| Dexcom, INC. | $163.62 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $117.19 | 2025 | Zoryve |
| Exact Sciences Corporation | $52.10 | 2024-2025 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $45.10 | 2024 | |
| 3b Medical, INC. | $27.49 | 2025 | Luna |
| Heartflow, INC. | $22.75 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.79 | 2024 | Edarbyclor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khanh Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.